APLT News and Press, Applied Therapeutics Inc. From 01/03/22

Shares of Applied Therapeutics (NASDAQ: APLT) , a clinical-stage biopharmaceutical company, are sliding today in response to upsetting news regarding its lead candidate. It turns out the Food and Drug Administration (FDA) wasn't on board with accelerated approval of AT-007 based on ...

NEW YORK, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today provided a regulatory update ...

NEW YORK, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the initiation of a...

NEW YORK, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, has announced a symposium and poste...

Applied Therapeutics (NASDAQ:APLT): Q3 GAAP EPS of -$1.09 beats by $0.01. Cash and cash equivalents of $70.21M. Press Release For further details see: Applied Therapeutics EPS beats by $0.01

Data from pilot trial of AT-007 in SORD deficiency expresses substantial and significant reduction in sorbitol Data from the ACTION-Galactosemia Kids study demonstrates statistically significant reduction in plasma galactitol NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- App...

Substantial and significant reduction in sorbitol Company plans to initiate registrational trial by end of 2021 Company to host conference call and webcast today at 8:30 a.m. ET NEW YORK, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), ...

Substantial and statistically significant reduction in plasma galactitol of 40% with new weight-based dosing parameters Baseline galactitol levels clearly correlated with baseline clinical functional outcomes NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, ...

Substantial and statistically significant reduction in plasma galactitol Baseline analysis demonstrates clear relationship between plasma galactitol level and severity of disease in pediatric Galactosemia patients NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Applied Therap...

Gainers: Support.com SPRT +173%. NeuroMetrix (NASDAQ:NURO) +90%. Navios Maritime Acquisition NNA +56%. Vinco Ventures (NASDAQ:BBIG) +49%. Aterian (NASDAQ:ATER) +31%. Marin Software Incorporated (NASDAQ:MRIN) +29%. Gambling.com Group GAMB +29%. Bill.com BILL +28%. Meta Mate...